Shares of PepGen (NASDAQ: PEPG) surged nearly 93% after the company reported promising Phase 2 clinical trial results for an experimental drug targeting myotonic dystrophy type 1 (DM1), a rare genetic disease that causes progressive muscle weakness.

‍

DM1 affects an estimated 110,000 people across the United States and European Union. Patients often struggle with muscle weakness and difficulty relaxing their muscles after using them. The disease can also affect the heart and lungs.

‍

There are currently no approved treatments that address the underlying genetic cause of DM1, leaving PepGen with a potentially significant commercial opportunity.

‍

PepGen reports encouraging clinical results

‍

In PepGen's Phase 2 trial, six patients received four monthly doses of its experimental drug, PGN-EDODM1. After 13 weeks, researchers reported an average 46.5% improvement in a biological measurement called RNA splicing correction, compared with 6.8% in a pooled placebo group.

‍

Essentially, DM1 interferes with how cells process genetic instructions needed to produce proteins. PepGen's drug is designed to correct those errors and potentially improve muscle function.

‍

According to the company, the 46.5% result represents the highest level of splicing correction reported in a multiple-dose DM1 study.

‍

Researchers also observed improvements in physical abilities after 16 weeks of treatment:

‍

  • Hand grip strength improved 16.2%.
  • The time needed to open a clenched hand improved 53%.
  • Walking and mobility tests showed improvements.

‍

If these results hold up in larger studies, PepGen could be developing a treatment that addresses both the underlying disease and its symptoms.
‍

The next clinical results could be critical

‍

PepGen is now testing a higher dose, with additional results expected in the first half of 2027. More clinical data are also anticipated in January.

‍

The company still faces substantial clinical and regulatory risks, and its experimental drug remains years away from potential commercialization. That said, these early results suggest PGN-EDODM1 could become a meaningful treatment for a disease with few therapeutic options.

‍

Source: https://investors.pepgen.com/news-releases/news-release-details/pepgen-announces-positive-phase-2-freedom2-dm1-10-mgkg-results

‍